ALKS


Also found in: Medical.
AcronymDefinition
ALKSAlkermes, Inc. (stock symbol)
References in periodicals archive ?
Biopharmaceutical company Alkermes plc (NASDAQ:ALKS) said on Wednesday that it has successfully filed its New Drug Application (NDA) for ALKS 5461 with the US Food and Drug Administration for the adjunctive treatment of major depressive disorder (MDD).
ALKS 7106 represents a new class of analgesic agents known as potent opioid modulators, designed for the treatment of pain with low potential for abuse and overdose, liabilities associated with opioid analgesics.
ALKS 33 was designed to provide minimally metabolized, highly potent, and sublingually bioavailable mu antagonism to allow for effective coformulation of the two agents.
DUBLIN -- Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 1 study of its new antipsychotic candidate, ALKS 3831, a combination of a proprietary drug molecule, ALKS 33, and olanzapine, a molecule that is commercially available under the name ZYPREXA([R]).
According to the terms of the contract, Biogen will receive an exclusive, worldwide license to commercialise ALKS 8700 and will pay Alkermes a mid-teens royalty on worldwide net sales of the product.
Indeed, ALKS 5461 may represent a new rapid-onset treatment approach for depression and other psychiatric disorders, such as addictive disorder, he said.
We had predetermined the product profile we needed to observe in order to continue to advance ALKS 37 into phase 3 clinical studies.
Under the terms of the agreement, Biogen will receive an exclusive, worldwide license to commercialize ALKS 8700 and will pay Alkermes a mid-teens royalty on worldwide net sales of ALKS 8700.
Biopharmaceutical company Alkermes (NasdaqGS:ALKS) reported on Monday the launch of a randomized, double-blind, parallel-group study designed to evaluate the exploratory metabolic profile of ALKS 3831 when compared to olanzapine for the treatment of schizophrenia under the ENLIGHTEN pivotal programme.
In the phase 1/2 clinical study, ALKS 5461 was shown to significantly reduce depressive symptoms, as measured by the Hamilton Depression Rating Scale (HAM-D17; a standard, clinician-assessed measure of depression severity), in patients with MDD who received ALKS 5461 for the seven-day treatment period.
Biopharmaceutical company Alkermes (NasdaqGS:ALKS) reported on Monday the start of a phase 1 clinical study of ALKS 7106 for the treatment of pain.
Study Showed Significant Reduction in Severity of Depression in Patients Treated With ALKS 5461 -